Johnson & Johnson submits emergency use listing to WHO for COVID-19 vaccine

Reuters

4 years ago

A pharmacist prepares the Johnson & Johnson Covid-19 vaccine to administer to health care workers at the government hospital in Klerksdorp, South Africa, Thursday, Feb. 18, 2021. South Africa started the rollout of vaccines Wednesday with South African President Cyril Ramaphosa among the first in his country to receive the vaccine in the inoculation drive in the country. (AP Photo/Shiraaz Mohamed)

NEW BRUNSWICK, N.J. (Reuters) — Johnson & Johnson said on Friday it had submitted for emergency use listing of its COVID-19 vaccine to the World Health Organization (WHO).

The company said the process is a prerequisite to supply vaccines to the COVAX vaccine program co-led by WHO, which aims to deliver doses to poor and middle-income countries.

J&J entered into an agreement in December in support of the COVAX program.

The company and Gavi, which also co-leads the COVAX program, expect to enter into an advance purchase agreement that would provide up to 500 million doses of the single-dose vaccine to COVAX through 2022, J&J said.